Endocarditis medical therapy: Difference between revisions
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
Line 787: | Line 787: | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float:left; width:48em" cellpadding="0" cellspacing="0"; | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float:left; width:48em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Suspected Bartonella, (culture negative)}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Suspected Bartonella, (culture negative)}}'' | ||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone sodium]] 2 g per 24 h IV/IM in 1 dose x 6 wks'''''<BR>''PLUS''<BR>▸ '''''[[Gentamicin|Gentamicin sulfate]] 1 mg per kg q8h IV/IM x 2 wks''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone sodium]] 2 g per 24 h IV/IM in 1 dose x 6 wks'''''<BR>''PLUS''<BR>▸ '''''[[Gentamicin|Gentamicin sulfate]] 1 mg per kg q8h IV/IM x 2 wks''''' | ||
Line 793: | Line 795: | ||
|- | |- | ||
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Doxycycline]] 100 mg per kg q12h IV/PO x 6 wks''''' | |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Doxycycline]] 100 mg per kg q12h IV/PO x 6 wks''''' | ||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatrics dose}}'' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone sodium]] 100 mg/kg per 24 h IV/IM once daily x 6 wks''''' <BR>''PLUS''<BR> ▸ '''''[[Gentamicin|Gentamicin sulfate]] 1 mg per kg q8h IV/IM x 2 wks''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |''WITH / WITHOUT'' | |||
|- | |||
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Doxycycline]] 2–4 mg per kg per 24 h IV/PO in 2 equally divided doses''''' | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Documented Bartonella, (culture positive)}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Documented Bartonella, (culture positive)}}'' |
Revision as of 15:11, 17 January 2014
Endocarditis Microchapters |
Diagnosis |
---|
Treatment |
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
Case Studies |
Endocarditis medical therapy On the Web |
Risk calculators and risk factors for Endocarditis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Ahmed Zaghw, M.D. [3]
Overview
Blood cultures should be drawn prior to instituting antibiotics to identify the etiologic agent and to determine its antimicrobial susceptibility. Older antibiotics such as penicillin G, ampicillin, nafcillin, cefazolin, gentamycin, ceftriaxone, rifampin and vancomycin are the mainstays of therapy.
Timing of Initiation of Antibiotics
Antibiotic therapy for subacute or indolent disease can be delayed until results of blood cultures are known; in fulminant infection or valvular dysfunction requiring urgent surgical intervention, begin empirical antibiotic therapy promptly after blood cultures have been obtained.
Duration of Antibiotic Therapy
The duration for native valve endocarditis is often 4 weeks. For prosthetic valve endocarditis (including the presence of a valve ring), treatment should be continued for 6 to 8 weeks. For each infective agent, the preferred antimicrobial agent, dose, and duration is listed below.
Empirical Antibiotic Therapy
- Antibiotic therapy for subacute hemodynamically stable disease, and in those who have received antibiotics recently can be delayed waiting for the results of blood cultures, as this delay allows an additional blood cultures without the confounding effect of empiric treatment, which is very important in determining the causing pathogens.[1]
- On the other hand, the rapid progression of acute cases necessitate the start of empirical treatment antibiotic therapy once the blood cultures have been collected.
- Empirical therapy is needed for all likely pathogens, certain antibiotic agents, including aminoglycosides, is preferably avoided for its toxic effects.
- Clinical course of infection beside the epidemiological features should be considered upon selecting empirical treatment regimen.
- Consultation with an infectious disease specialist for the selection of one of the antibiotic regimens is recommended (see therapy for culture-negative endocarditis). [2]
Treatment Based Upon Infectious Agent[3]
Streptococci
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus bovis
Viridans Group Streptococci and Streptococcus bovis Highly Penicillin-Susceptible
Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis |
---|
Preferred Regimen ( 4 wks ) |
Adult dose |
▸ Penicillin G sodium † 12–18 million U/24 h IV either continuously or in 4-6 equally divided doses x 4 Wks OR ▸ Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 4 Wks |
Pediatric dose ₳ |
▸ Penicillin G sodium 200 000 U/kg q24h IV either continuously or in 4-6 equally divided doses x 4 Wks OR ▸Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 4 Wks |
Alternative Regimen ( 2 wks ) |
Adult dose |
▸ Penicillin G sodium‡ 12–18 million U/24 h IV either continuously or in 6 equally divided doses x 2 Wks OR ▸ Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 2 Wks |
PLUS |
▸ Gentamicin sulfate ฿ 3 mg/Kg per 24h 1 dose x 2 Wks\ |
Pediatric dose |
▸ Penicillin G sodium 200 000 U/kg q24h IV in 4-6 equally divided doses x 2 Wks OR ▸Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 2 Wks |
PLUS |
▸ Gentamicin sulfate 3 mg/Kg per 24h 1 dose or 3 equally divided doses x 2 Wks |
Alternative Regimen |
Adult dose |
▸ Vancomycin hydrochloride ¶ 15 mg/kg q12h IV x 4 Wks Doses should not to exceed 2 g/24 h unless concentrations in serum are inappropriately low |
Pediatric dose |
▸Vancomycin hydrochloride 40 mg/kg per 24 h IV in 2–3 equally divided doses |
- Minimum inhibitory concentration ≤ 0.12 μg/mL.
- † Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function.
- ₳ Pediatric dose should not exceed that of a normal adult.
- ‡ 2-wk regimen not intended for patients with known cardiac or extracardiac abscess or for those with creatinine clearance of <20 mL/min, impaired 8th cranial nerve function, or Abiotrophia, Granulicatella, or Gemella spp infection; gentamicin dosage should be adjusted to achieve peak serum concentration of 3-4 μg/mL and trough serum concentration of >1 μg/mL when 3 divided doses are used; nomogram used for single daily dosing.
- ¶ Vancomycin therapy recommended only for patients unable to tolerate penicillin or ceftriaxone; vancomycin dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/mL and a trough concentration range of 10–15 μg/mL
- ฿ Other potentially nephrotoxic drugs (eg, nonsteroidal antiinflammatory drugs) should be used with caution in patients receiving gentamicin therapy. Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.
Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL)
|
Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Viridans Group Streptococci and Streptococcus Bovis
Viridans Group Streptococci and Streptococcus bovis Penicillin-susceptible strain (MIC ≤ 0.12 μg/mL)
|
- Dosages recommended are for patients with normal renal function.
- † Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min.
- ‡ Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.
Viridans Group Streptococci and Streptococcus bovis Penicillin relatively or fully resistant strain (MIC >0.12 μg/mL)
|
Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml
|
Relatively Penicillin-Resistant Streptococci, (MIC > 0.5 µg/ml)
|
Unable to tolerate Penicillin or Ceftriaxone
|
Enterococci
Native valve or prosthetic valve enterococcal endocarditis requires combination therapy with two antibiotics as the following:
Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin |
---|
Preferred Regimen |
Adult dose |
▸ Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks OR ▸Penicillin G sodium 18–30 million U. I.V. daily in 6 equally divided doses x 4–6 Wks |
PLUS |
▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 4-6 Wks |
Alternative Regimen |
▸ Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks |
Pediatric dose |
▸ Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; X 4–6 Wks OR ▸Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses X 4–6 Wks |
PLUS |
▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks |
OR (in penicillin hypersensitivity) |
▸ Vancomycin 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks |
Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin |
---|
Preferred Regimen |
Adult dose |
▸ Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks OR ▸Penicillin G sodium 24 million U. I.V. continuously or in 6 equally divided doses x 4–6 Wks |
PLUS |
▸Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks |
Alternative Regimen |
▸ Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks PLUS ▸Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks |
Pediatric dose |
▸ Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; X 4–6 Wks OR ▸Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses X 4–6 Wks |
PLUS |
▸Streptomycin sulfate 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses |
OR (in penicillin hypersensitivity) |
▸ Vancomycin 40 mg/kg per 24 h
IV in 2 or 3 equally divided doses X 4–6 Wks |
Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin
β-Lactamase–producing strain |
---|
Preferred Regimen |
Adult dose |
▸ Ampicillin-sulbactam 12 g/24 h IV in 4 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks |
Pediatric dose |
▸ Ampicillin-sulbactam 300 mg/kg per 24 h IV in 4 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks |
Alternative Regimen |
▸Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks |
Pediatric dose |
▸ Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks |
Intrinsic penicillin resistance |
---|
Adult dose |
▸Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks |
Pediatric dose |
▸ Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks |
Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin
E faecium |
---|
Adult dose |
▸ Linezolid 1200 mg/24 h IV/PO in 2 equally divided doses x ≥8 Wks OR ▸Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses x ≥ 8 Wks |
Pediatric dose |
▸ Linezolid 30 mg/kg per 24 h IV/PO in 3 equally divided doses ≥8 Wks OR ▸Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses ≥8 Wks |
E faecalis | |
---|---|
Adult dose | |
Preferred Regimen | |
▸ Imipenem/cilastatin 2 g/24 h IV in 4 equally divided doses x ≥8 Wks PLUS ▸Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks | |
Pediatric dose | |
▸ Imipenem/cilastatin 60–100 mg/kg per 24 h IV in 4 equally divided doses x ≥8 Wks PLUS ▸Ampicillin sodium 300 mg/kg per 24 h IV in 4–6 equally divided doses x ≥ 8 Wks | |
Alternative Regimen | |
Adult dose | |
▸ Ceftriaxone sodium 4 g/24 h IV/IM in 2 equally divided doses x ≥8 Wks PLUS ▸Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks | |
Pediatric dose | |
▸ Ceftriaxone sodium 100 mg/kg per 24 h IV/IM in 2 equally divided doses x ≥8 Wks PLUS ▸Ampicillin sodium 300 mg/kg per 24 h IV in 4–6 equally divided doses x ≥ 8 Wks |
Staphylococci
Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material
Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material
|
- † Penicillin G 24 million U/24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin susceptible (MIC ≤ 0.1 μg/mL) and does not produce β-lactamase.
- ‡ Gentamicin should be administered in close temporal proximity to vancomycin, nafcillin, or oxacillin dosing.
Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity in the Absence of Prosthetic Material
|
Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci
Oxacillin-susceptible strains in the Presence of Prosthetic Material
|
Oxacillin-resistant strains in the Presence of Prosthetic Material
|
HACEK Organisms
HACEK organisms are more indolent and the infection is less complicated.
|
- HACEK: Haemophilus parainfluenzae, H aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
- † Patients should be informed that IM injection of ceftriaxone is painful.
- ‡ Dosage recommended for patients with normal renal function.
- ¶ Fluoroquinolones are highly active in vitro against HACEK microorganisms. Published data on use of fluoroquinolone therapy for endocarditis caused by HACEK are minimal.
Culture Negative Endocarditis
- Clinical course of infection beside the epidemiological features should be considered upon selecting treatment regimen.
- Patients should be divided into 2 groups:
Patients Who Received Antibiotic Therapy Before the Blood Culture
- Patients with acute clinical presentations with native valve infection: coverage of S. aureus should be followed as detailed in proven staphylococcal disease.
- Patients with subacute presentation: antibiotic coverage for S. aureus, viridians group streptococci, and enterococci should be considered.
- Antibiotics for HACEK group of organism also should be considered.
- Symptomatic patients with prosthetic valve and culture negative infection within 1 year of valve replacement should receive vancomycin to cover the oxacillin-resistant staphylococci.
- Symptomatic patients with prosthetic valve and culture negative infection within 2 months of valve replacement should also receive cefepime for gram negative bacilli coverage.
- Symptomatic patients with prosthetic valve more than 1 year, the most likely causing organisms are oxacillin-susceptible staphylococci, viridians group streptococci, and enterococci. Antibiotic coverage for those organisms should be continued for at least 6 weeks.
Patients with Culture-Negative Endocarditis and Suspected Infection with Uncommon Endocarditis Pathogens
- Examples of these pathogens include Bartonella species, Chlamydia species, Coxiella burnetii, Brucella species, Legionella species, Tropheryma whippleii, and non-Candida fungi.
- The most common pathogens that have been reported with culture-negative endocarditis are Bartonella species, Coxiella burnetii, and Brucella species.
- Antibiotic therapy for these pathogens should include aminoglycosides for at least 2 weeks.
- Therapeutic regimens for Bartonella endocarditis based on the epidemiological risk and high index of suspicion.[2]
Native Valve Culture Negative Endocarditis
|
Prosthetic Valve Culture Negative Endocarditis
|
Bartonella Culture Negative Endocarditis
|
References
- ↑ Braunwald, Eugene; Bonow, Robert O. (2012). Braunwald's heart disease : a textbook of cardiovascular medicin. Philadelphia: Saunders. ISBN 978-1-4377-2708-1.
- ↑ 2.0 2.1 Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=
ignored (help) - ↑ Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.